Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor
neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration
is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Brian Wainger
Collaborators:
ALS Association GlaxoSmithKline Harvard University Massachusetts General Hospital